🚨 Trump’s 25% Tariff on Indian Pharma – What It Means for Our Pharma Giants! 💊📉 The U.S. has proposed a 25% import tariff on pharmaceutical products, and Indian drugmakers—who supply 40% of America’s generic prescriptions—are in the crosshairs! 🇮🇳➡️🇺🇸 🔹 Biggest U.S. Revenue Exposure 📊 Dr. Reddy’s, Aurobindo Pharma – 46% 📊 Lupin – 37% 📊 Cipla – 28% 🔹 Projected Earnings Impact (10% Tariff) 📉 Dr. Reddy’s – 🔻6.5% 📉 Zydus Lifesciences – 🔻6% 📉 Aurobindo – 🔻5.5% 📉 Lupin – 🔻4.5% 📉 Cipla – 🔻4% 💡 What This Means: 📌 Indian pharma stocks could take a hit if the tariff goes through! 📌 U.S. drug prices may rise as supply chains get disrupted. 📌 Companies might expand to other markets or set up U.S. plants to avoid tariffs. 🌍 The global pharma landscape is shifting fast! What are your thoughts on this move? Drop a comment below! 👇💬